The Oncomine Dx Target Test as a companion diagnostic has received FDA approval to identify RET fusion-positive, metastatic non-small cell lung cancer patients who are candidates for Gavreto (pralsetinib), a targeted therapy developed by Blueprint Medicines.
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
